You will now be redirected to the GD3 website
Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.
Learn more about GD3Disease Modeling
Phenotypic characterization of genetically modified animals plays a critical role in the drug target validation process, understanding potential on-target liabilities, and potential discovery of new indications. Researcher needs vary, depending on the stage and specific goals of a drug discovery and development program. GD3 scientists are experts and will custom-design each phenotyping project to meet the project goals best and provide comprehensive data analysis and interpretation.
GD3 offers in-depth, disease-oriented phenotyping assessment with expertise in autoimmune and inflammatory disorders, oncology, metabolism, diabetes, obesity and other indications. By multiplexing bioassays spanning multiple therapeutic areas, we provide a powerful tool for assessing potential on-target side effects and early identifying new therapeutic indications for genetic targets. Sequential evaluation of animals in well-designed and multiplexed validated bioassays maximizes the quality data set per animal, delivering significant savings in time, cost and animal resources.
We have years of experience characterizing novel genetically modified rodents for therapeutically relevant phenotypes. Our in vivo testing capabilities are supported by biochemical and molecular biology techniques and functional assays using primary cell cultures established from various mouse tissues derived from disease models and normal animals. These assays provide tools to study the mechanism of action of various test therapeutics or potential target genes and to explore drug efficacy biomarkers.
Learn more about